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Background: Imatinibmesylate (imatinib) is a small molecule tyrosine kinase inhibitor administered to patients with
chronic myelogenous leukemia and gastrointestinal stromal tumor. Although imatinib-associated interstitial lung
disease is uncommon, a few cases have been reported so far. However, in all these cases interstitial lung disease
developed during the use of imatinib. The present case is the first report of imatinib-induced interstitial lung
disease developing after discontinuation of the drug.
Case presentation: A 51-year-old woman was administered oral imatinib for gastrointestinal stromal tumor. Ten
weeks later, imatinib was discontinued because of facial edema. On this occasion, chest radiography showed no
abnormal findings. However, 2 weeks after discontinuation of imatinib, she developed fever, dry cough, and
dyspnea. Chest radiography and computed tomography showed diffuse interstitial infiltrates in both lungs.
Examination of bronchoalveolar lavage fluid showed an increased proportion of lymphocytes. Imatinib-induced
interstitial lung disease was suspected, because no other cause was evident. After administration of corticosteroids,
her clinical condition and chest radiographic findings improved.
Conclusion: We report a unique case of imatinib-induced interstitial lung disease that developed 2 weeks after
discontinuation of the drug. Physicians should consider occurrence of imatinib-induced interstitial lung disease
even after discontinuation of the drug.
Keywords: Drug-induced interstitial lung disease, Drug-induced lung injury, Drug induced pneumonitis, Drug
lymphocyte-stimulating test, ImatinibmesylateBackground
Imatinibmesylate is a tyrosine kinase inhibitor (TKI) with
activity against platelet-derived growth factor receptors
(PDGFR-α and -β), discoidin domain receptors (DDR1
and DDR2), c-kit, and c-Abl. It is administered to patients
with chronic myelogenous leukemia and gastrointestinal
stromal tumor (GIST) [1,2].
Despite the encouraging data from cellular and animal
models of lung fibrosis and the increasing use of imatinib
to treat other inflammatory and fibrotic diseases such as
scleroderma [3] and pulmonary arterial hypertension [4],* Correspondence: kakugawa@nagasaki-u.ac.jp
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distribution, and reproduction in any mediumfew cases of imatinib-associated interstitial lung disease
(ILD) have been reported so far [5] (and references
therein). In all of these reported cases, ILD developed
during the use of imatinib.
The present case is the first report about imatinib-
induced ILD that developed after discontinuation of the
drug.Case presentation
A 51-year-old Japanese woman with no medical history
was administered oral imatinib 400 mg daily for GIST.
Ten weeks later, imatinib was discontinued because of
facial edema. On this occasion, chest radiography showed
no abnormal findings (Figure 1A). However, 2 weeks after
discontinuation of imatinib treatment, she developed fever,tral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
Figure 1 Images of the patient’s lungs. Chest radiography performed on the day imatinib was discontinued (A) showed no abnormal findings.
Chest radiography on admission (B) revealed bilateral reticular shadows in both mid and lower lung fields. Chest high-resolution computed
tomography (HRCT) scans obtained on admission (D) revealed diffuse interstitial infiltrates in both lungs, predominantly along the
bronchovascular bundles extending to subpleural regions. Two months after corticosteroid therapy, chest radiography (C) and HRCT scans
(E) indicated remarkable improvement.
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http://www.mrmjournal.com/content/7/1/48dry cough, and dyspnea on exertion. Because her symp-
toms had remained unchanged for a month, she was
referred to the respiratory medicine department in our
hospital. She had taken no other drugs or alternative
medicines.
The patient was a non-smoker. On admission, her oxy-
gen saturation was 94% in room air, and body temperature
was 36.2°C. Respiratory sounds were normal. Neither
facial nor leg edema was observed. Arterial blood gas ana-
lysis in room air revealed a pH of 7.401; PaO2, 80.7 torr;
and PaCO2, 40.1 torr. White blood cell count was 8,600/
mm3 with 80.1% neutrophils, 11.8% lymphocytes, 5.4%
monocytes, 2.6% eosinophils, and 0.1% basophiles. C-
reactive protein was negative (<0.30 mg/dL). Levels of
lactate dehydrogenase activity were slightly elevated
(273 IU/L). Serum Krebs von den Lungen-6 (KL-6) and
surfactant protein (SP)-D levels were normal (477 U/mL
and 97.9 ng/mL, respectively). Anti-nuclear antibody and
other autoantibodies to specific antigens were all negative.
Pneumococcal and Legionella urinary antigens were nega-
tive. Cultures of blood and sputum to detect bacteria,
fungi, and mycobacteria were all negative. Results of
serological tests for Mycoplasma pneumoniae and Chla-
mydophilapneumoniae were negative; test results for β-D-glucan and cytomegalovirus antigen were also negative.
The result of a drug lymphocyte-stimulating test (DLST)
against imatinib was negative (Table 1).
Chest radiography on admission revealed bilateral re-
ticular shadows in both mid and lower lung fields
(Figure 1B). Chest high-resolution computed tomography
(HRCT) scans revealed diffuse interstitial infiltrates in
both lungs, predominantly along the bronchovascular
bundles extending to subpleural regions (Figure 1D).
Examination of bronchoalveolar lavage (BAL) fluid of the
right B4 bronchus showed an elevated total cell count
(4.35 × 105 cells/mL) including 8% macrophages, 4% neu-
trophils, 71% lymphocytes, and 10% eosinophils. The
CD4/CD8 ratio of lymphocyte subsets was 1.29 (Table 2).
Cultures of BAL fluid were negative for fungal, bacterial,
or mycobacterial pathogens. Cytological findings of BAL
fluid showed a large number of lymphocytes, but no
malignancies (Figure 2A). Lung specimens of the right B2b
bronchus obtained by transbronchial lung biopsy showed
mixed intra-alveolar and interstitial changes, with loose
fibrous plugs and giant cells in intra-alveolar regions, and
fibroblasts and lymphocytes in interstitial tissue, which
was suggestive of a hypersensitivity pneumonitis pattern
(Figure 2B, 2C).
Table 1 Laboratory data on admission
Hematology






RBC 4.24 × 106/mm3
Hemoglobin 11.8 g/dL
Hematocrit 36.8%
Platelets 246 × 103/mm3






Total protein 6.6 g/dL
Albumin 3.8 g/dL
Total bilirubin 0.5 mg/dL

























Table 1 Laboratory data on admission (Continued)
pneumoniaeIgG (-)
C. pneumoniae IgA (-)
β-D-Glucan (-)
CMV Ag (C7-HRP) (-)
DLST against imatinib (-)
RBC, red blood cell; ALT, alanine aminotransferase; ALP, alkaline phosphatase;
ANA, anti nuclear antibody; AST, aspartate aminotransferase; BUN, blood urea
nitrogen; C. pneumoniae, Chlamydophilapneumoniae; ChE, cholinesterase; CMV,
cytomegalovirus; CRP, C-reactive protein; DLST, drug lymphocyte-stimulating
test; KL-6, Krebs von den Lungen-6; LDH, lactate dehydrogenase; MPO-ANCA,
myeloperoxidase-antineutrophil cytoplasmic antibody; PR3-ANCA, proteinase
3-antineutrophil cytoplasmic antibody; RF, rheumatoid factor; SP-D, surfactant
protein-D; WBC, white blood cell.
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negative, drug-induced ILD caused by imatinib was sus-
pected, because no other cause was evident. High-dose
methylprednisolone (1 g/day intravenously for 3 days)
was administered, followed by oral prednisolone (40 mg/
day), which was then tapered off gradually. This resulted
in an immediate improvement in clinical condition and
a gradual improvement in chest radiographic findings
(Figure 1C, 1E). She underwent total gastrectomy and
partial hepatectomy for the treatment of GIST one year
after the initiation of the corticosteroid treatment with
no recurrence of ILD.
Discussion
We encountered a unique case of imatinib-induced ILD,
which developed after discontinuation of the drug. In
addition to our report, 13 other case reports of imatinib-
induced ILD have been published. All of these patients
developed imatinib-induced ILD during administration
of the drug (2 to 44 weeks), and in all cases, the condi-
tion was successfully treated with steroid therapy and
drug discontinuation [5] (and references therein).
In one of these reports, Ohnishi et al. reported that 27
of 5,500 patients who were administered imatinib were
diagnosed with drug-related ILD. Of the 27 patients with
drug-induced ILD, 23 were diagnosed with CML and 4
with GIST. The median period until development of ILD
was 49 days (range, 10–282 days). Results of DLST
against imatinib were available for 9 patients, and all
were negative. Imatinib-related ILD responded well to
corticosteroid treatments [6].Table 2 Findings of bronchoalveolar lavage fluid






Figure 2 Cytological and histopathological findings. Cytological findings of BAL fluid (A) showed a large number of lymphocytes, but no
malignancies. Lung specimens of the right B2b bronchus obtained by transbronchial lung biopsy (B, C) showed mixed intra-alveolar and
interstitial changes, with loose fibrous plugs and giant cells in intra-alveolar regions, and fibroblasts and lymphocytes in interstitial tissue, which
was suggestive of a hypersensitivity pneumonitis pattern.
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treatment, she developed fever, dry cough, and dyspnea on
exertion 2 weeks after discontinuation of imatinib. HRCT
scans revealed bilateral interstitial infiltrates predomin-
antly along the bronchovascular bundles. Bronchoscopic
examination showed no pathogens or malignancies.
Although the result of a DLST against imatinib was nega-
tive, imatinib-induced ILD was the most probable diagno-
sis because no other cause was evident. Although
uncommon, late-onset pneumonitis caused by cytotoxic
anti-neoplastic drugs occasionally occurs even after dis-
continuation of the drugs. To the best of our knowledge,
the present case is the first report of development of
imatinib-induced ILD after discontinuation of the drug.
Imatinib plasma concentrations have been reported to
increase by 2- to 3-fold when reaching steady state dur-
ing 400 mg once-daily administration (to 2.6 ± 0.8 μg/
mL at peak and 1.2 ± 0.8 μg/mL at trough), exceeding
the 0.5 μg/mL (1 μmol/L) concentration required for
tyrosine kinase inhibition in vitro. The terminal elimin-
ation half-life of imatinib is approximately 18 hours [7].
However, no evidence of tumor growth was noted in
nude mice injected with the Bcr/Abl-positive human
leukemia cell line KU812 and receiving imatinib at
160 mg/kg orally every 8 hours for 11 consecutive days,
for up to 240 days [8]. Accordingly, the biological acti-
vity of imatinib may continue after administration hasceased; this may be one of the explanations for occur-
rence of drug-induced ILD after discontinuation of the
drug. Another explanation can be derived from histo-
pathological findings. A recent evidence supports the
prominent role of T-helper 1 cell-mediated hypersensi-
tivity with an imbalance of T-lymphocyte subsets in the
late phase of hypersensitivity pneumonitis, although
the deposition of immune complex may participate in
the acute form of the disease as well as in the early
phase of the chronic form [9] (and references therein).
This delayed cell-mediated hypersensitivity mechanism
may have played a role in the pathogenesis of the
present case.
The proliferative activities of PDGFR and other tyro-
sine kinases in the pathogenesis of idiopathic pulmo-
nary fibrosis led to in vivo and in vitro investigations to
assess the use of imatinib as a potential inhibitor of lung
fibrosis. Imatinib was identified as a potent inhibitor of
lung fibroblast-to-myofibroblast transformation and
proliferation as well as extracellular matrix production
through inhibition of PDGF and transforming growth
factor (TGF)-β signaling [10]. In addition, imatinib
inhibits lung fibrosis in bleomycin models of lung
fibrosis [11,12]. The interesting clinical question of
why imatinib, which has an antifibrotic effect, causes
drug-induced ILD remains to be answered in a future
study.
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Pulmonary toxicities caused by targeted agents are rare
but important to recognize even after discontinuation
of the drug. We have reported a unique case of
imatinib-induced ILD that developed after disconti-
nuation of the drug. Physicians should consider the
occurrence of imatinib-induced ILD even after discon-
tinuation of the drug.
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